Recent Updates
Recently added Catalysts
PRAX Positive Sentiment

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Friday, May 10, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Praxis Precision Medicines, a clinical-stage biopharmaceutical company, has announced that it will release its financial results for the first quarter of 2024 on May 13, 2024, prior to the opening of U.S. financial markets. The company specializes in developing therapies for central nervous system disorders linked to neuronal imbalances. This upcoming report may provide insights into the company's financial health and its ongoing research efforts in CNS therapies.
Price reaction · baseline $50.09 (2024-05-09 close) · hit after-hours · 1 other PRAX headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Praxis Precision Medicines is advancing in its financial reporting, indicating growth.
  • The company is focused on developing therapies for CNS disorders, addressing a critical need.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

When will Praxis Precision Medicines report financial results?

Praxis Precision Medicines will report its first quarter 2024 financial results on May 13, 2024.

What is the focus of Praxis Precision Medicines?

The company develops therapies for CNS disorders by addressing neuronal excitation-inhibition imbalance.

What stock exchange is Praxis Precision Medicines listed on?

Praxis Precision Medicines is listed on the NASDAQ under the ticker PRAX.

What does a Reader Account offer?

A Reader Account allows you to easily send emails directly to the contact for the release.

What is the significance of May 13, 2024, for investors?

This date marks the announcement of the financial performance for the first quarter 2024.

ShareAdd on Google
Tags: PRAX Viatris Investor Conferences Healthcare financial results CNS disorders biopharmaceutical neuron imbalance
Last updated: May 10, 2024

Biotech snapshot

Cash runway
$1374M liquidity · $26M/mo burn
~53 mo
Minimal dilution risk
Lead asset
vormatroginePhase 3
Epilepsy, Tonic-Clonic →

Catalyst track record

+61%
best trade around PRAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for PRAX.

See every catalyst's timing & PoA →